As per the current market research conducted by CMI Team, the Global Cell Culture Media Market for Regenerative Medicines size is expected to record a CAGR of 12.4% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 4,079 Million. By 2032, the valuation is anticipated to reach USD 11799 Million.
Cell culture media, often known as growth media, is a term for any gel or liquid designed to promote cellular development in an enclosed environment. When cells, organs, or tissues are extracted from living species, they must be kept in a suitable artificial environment; hence, a culture media plays an important part in cell culture technology, facilitating in vitro cellular research.
The medium provides the nutrients required for cell cultures to survive and grow. The growth media also has the proper osmolality and pH. Regenerative medicine, on the other hand, tries to repair tissue or organs that have been destroyed by illness, trauma, or congenital abnormalities. Tissue engineering, cellular therapy, medicinal gadgets, and artificial organs all involve regenerative medicines.
North America is expected to be one of the most alluring areas during the forecast period, accounting for the majority of market revenue. This substantial proportion might be attributed to the growth of the pharmaceutical and biomedical industries, the rising proportion of permits for cell culture-based stem cell therapy, the rising prevalence of chronic diseases, investment and funding in cell-based research.
Additional government research programs, technological advances and advances in cell culture usage, oncology medical trials, and the presence of global biotechnology and research facilities in the region are projected to fuel sales growth in North America.
On the other end, the UK is home to around one-third of all advanced therapeutic pharma industry SMEs in Europe. Several UK organizations offer guidance, support, and vital information at every stage of the development of electronic health and wellness solutions. The market is predicted to increase rapidly because of the success of pan-European programs (such as CHRODIS and CHRODIS PLUS), the government’s attempts, public and commercial research funders, and collaborative science and research initiatives in the field of regenerative medicine.
Stem cell therapy is one of the most innovative applications of regenerative medicine. Stem cell therapy, which incorporates stem cells or related by-products, increases the body’s inherent capacity to mend injured, diseased, or dysfunctional tissue. Stem cells are manipulated to create specific cells such as blood cells, heart muscle cells, or brain cells.
The patient can then receive the specific cells via an implant. Because stem cells can generate every form of tissue in the human body, they are very likely to be employed in the regeneration and repair of tissues in the future. Recent developments in stem cell research have opened up new paths for the treatment of disorders and afflictions for which there are no long-term cures.
Regeneration medication helps to cure the damage quickly and prevent surgery. Since the patient’s cells are employed in the procedure, the danger of the therapy is low. Overall, all of these aspects contribute to the growing popularity and need for cell-based therapy in regenerative medicine.
The ethical concern regarding the research related to cell therapy regeneration medicine is restraining the growth of the cell culture media market. Contamination and misidentification of cell lines are the two main elements that provide a problem for cell growth in a cell culture medium.
According to ncbi.nlm.nih.gov, Cross-contamination can occur when dealing with various cell lines in culture and unintentionally using a pipette multiple times. The infected cell line multiplies faster than the original cells, swiftly taking over the population, and altering the culture’s identity. Since cells from many origins might have similar morphologies, the alterations frequently go unnoticed.
Mycoplasma, viruses, or other organisms can infect cultured cells, which can change the way the cells behave. Without any contamination from the outside, cell lines in culture can indeed alter over time. Cells can have mutations, epigenetic alterations, and chromosomal duplications or rearrangements that modify their characteristics when they are cultured in the lab generation after generation.
An increase in investment in regeneration medicine development by commercial and governmental entities is expected to drive the cell culture medium for regeneration medicine industry dynamics. The rising prevalence of chronic illnesses and the rising expenses of healthcare in both developed and developing countries are just a few of the primary forces driving manufacturers to seek better solutions.
The companies are collaborating to boost their R&D capabilities to discover and commercialize cutting-edge remedies, guaranteeing that their clients may access them locally or globally. For instance, Orchard Therapeutics and Pharming Group N.V. collaborated in July 2021 to develop and commercialize OTL-105, an investigational ex vivo autologous Hematopoietic Stem Cell (HSC) cell therapy for the treatment of Hereditary Angioedema (HAE).
Furthermore, as a result of increased investment, businesses might merge and increase output to fulfil market demand. For example, in March 2018, SanBio Group and Hitachi Chemical Advanced Therapeutics Solutions, LLC signed an agreement for the development and contract manufacturing of regeneration drugs.
|Feature of the Report
|Market Size in 2023
|USD 4,548.6 Million
|Projected Market Size in 2032
|USD 11799 Million
|Market Size in 2022
|USD 4,079 Million
|CAGR Growth Rate
|By Product, Type and Region
|Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
|North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
|Request tailored purchasing options to fulfil your requirements for research.
According to the global Cell Culture Media Market for Regenerative Medicines analysis, based on product, the serum-free media segment gained a major share in the global market in 2021 and is expected to sustain its market share during the forecast period.
The use of serum-free medium (SFM) is an essential instrument that allows cell culture to be conducted with a predetermined set of circumstances that are as devoid of confounding factors as feasible. Rapidly expanding biopharmaceutical industries and rising production of regeneration medicine output are paving the way for the growth of serum-free media in the market.
According to the global Cell Culture Media Market for Regenerative Medicines trends, based on type, the liquid segment gained a major share in the market in 2021 and is expected to sustain its market share during the forecast period. With the quick mycobacterial growth and a high rate of isolation, a growing number of biologics and biosimilar producers, both downstream and upstream, are converting from premixed powders to liquid mediums.
Furthermore, liquid media decreases the risk of harmful exposure and makes production & development more versatile than solid media. Furthermore, ready-to-use liquid media removes the requirement for mixing vessels, balances, and the installation of a water for injection (WFI) loop, all of which are required when mixing powder media.
According to the global Cell Culture Media Market for Regenerative Medicines trends, based on region, the North American region gained a major share of the market in 2021 and is expected to sustain its market share during the forecast period.
The exponential growth is linked to the rise of the biomedical and pharmaceutical sectors, the increasing number of licenses for cell culture-based regenerative therapy, and the rising prevalence of illnesses such as cancer, and investment and financing in cell-based research. Increased government research initiatives, the development of new technologies and developments in cell culture applications, medical trials on cancer, and the existence of world-class biotechnology and research institutes in the area are expected to drive market expansion in North America.
- In July 2016, ThermoFisher Scientific Inc. introduced a new Thermo scientific pre-weigh dehydrated culture media to expand its product offering,
- In June 2017, Cell Culture Technologies launched SteMaxOne medium for human mesenchymal stem cells and stem cell lines to extend its product portfolio and client base. This medium is devoid of protein and peptides.
List of the prominent players in the global Cell Culture Media Market for Regenerative Medicines:
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Sartorius AG
- FUJIFILM Irvine Scientific Inc.
- Lonza Group AG
- STEMCELL Technologies Inc.
- PromoCell GmbH
- Cell Biologics Inc.
The global Cell Culture Media Market for Regenerative Medicines is segmented as follows:
- Serum-free Media
- Classical Media
- Stem Cell Culture Media
- Specialty Media
- Chemically Defined Media
- Other Cell Culture Media
- Liquid Media
- Semi-solid and Solid Media
- The U.S.
- The UK
- Rest of Europe
- South Korea
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- Rest of Latin America